Canadian Journal of Anaesthesia

, Volume 41, Issue 4, pp 291–294 | Cite as

RETRACTED ARTICLE: Reduction of postoperative nausea and vomiting with granisetron

  • Yoshitaka Fujii
  • Hiroyoshi Tanaka
  • Hidenori Toyooka
Reports of Investigation

Abstract

The antiemetic effects of granisetron, a selective 5-hydroxy-tryptamine type 3 receptor antagonist, on postoperative nausea and vomiting were studied and compared with placebo and metoclopramide in 60 patients undergoing general anaesthesia for major gynaecological surgery. The patients received a single iv dose of either granisetron (3 mg, n = 20) metoclopramide (10 mg, n = 20), or placebo (saline, n = 20) immediately after recovery from anaesthesia. The effects were assessed during the first three and the next 21 hr after recovery from anaesthesia by means of a nausea and vomiting score; 0 = no emetic symptoms, 1 = nausea, 2 = vomiting. The mean scores during 0–3 hr were 0.8, 0.1 and 0.1 after administration of placebo, metoclopramide and granisetron, respectively; the corresponding scores during 3–24 hr were 0.6, 0.5 and 0.1. The scores of the metoclopramide and the granisetron groups were different from the placebo group in the first three hours (P < 0.05). Although there were no differences in the scores during 0–3 hr between the metoclopramide and the granisetron groups, there were differences during 3–24 hr (P < 0.05). It is concluded that granisetron is superior to metoclopramide in the long-term prevention of postoperative nausea and vomiting after anaesthesia.

Key words

complications: nausea, vomiting vomiting: antiemetics granisetron, metoclopramide, incidence, nausea 

Résumé

Les propriétés antiémétiques postopératoires du granisetron, un antagoniste sélectif des récepteurs de type 3 de la 5-hydroxytryptamine, sont étudiées et comparées à un placébo et à la métoclopramide chez 60 patientes soumises à une anesthésie générale pour des opérations gynécologiques majeures. Les patients reçoivent une seule dose iv de granisetron (3 mg, n = 20), de métoclopramide (10 mg, n = 20) ou de placébo (soluté physiologique, n = 20) immédiatement après le réveil. Les effets sont évalués pendant les trois premières et les 21 heures suivantes au moyen d’une échelle de nausées et vomissements; 0 = aucun symptôme, 1 = nausées, 2 = vomissements. Les scores moyens de 0–3 h sont respectivement de 0,8, 0,1 et 0,1 après l’administration du placébo, de la métoclopramide et du granisetron; les scores correspondants de 3–24 h sont de 0,6, 0,5 et 0,1. Les scores des groupes métoclopramide et granisetron sont différents du groupe placébo pendant les trois premières heures (P < 0,05). On n’a pas trouvé de différences entre les scores de la période de 0–3 h entre les groupes métoclopramide et granisetron, mais il y avait des différences entre ces groupes pendant la période de 3–24 h (P < 0,05). On conclut que le granisetron est supérieur à la métoclopramide pour la prévention à long terme de la nausée et des vomissements postopératoires.

References

  1. 1.
    Madej T, Simpson K. Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following gynaecological surgery in day cases. Br J Anaesth 1986: 58: 879–83.PubMedCrossRefGoogle Scholar
  2. 2.
    McKenzie R, Wadhwa R, Uy N, et al. Antiemetic effectiveness of intramuscular hydroxyzine compared with intramuscular droperidol. Anesth Analg 1981; 60: 783–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Korttila K, Kauste A, Auvinen J. Comparison of domperidone, droperidol, and metoclopramide in the prevention and treatment of nausea and vomiting after balanced general anaesthesia. Anesth Analg 1979; 58: 396–400.PubMedCrossRefGoogle Scholar
  4. 4.
    Bodner M, White P. Antiemetic efficacy of ondansetron after outpatient laparoscopy. Anesth Analg 1991; 73: 250–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Andrews PLR, Bhandari P, Davey PT, Bingham S, Man HE, Blower PR. Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992; 28: S2-S6.CrossRefGoogle Scholar
  6. 6.
    Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 4369A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Kilpatrick GJ, Jones BJ, Tyers MB. The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography. Neurosci Lett 1988; 94: 156–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Fume H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs (I) — optimal dose-finding study. Journal of Clinical and Therapeutic Medicine 1990; 6: 49–61.Google Scholar
  9. 9.
    Fujii Y, Tanaka H. Postoperative anti-emetic effects of low dose droperidol. Masui 1993; 42: 694–7.PubMedGoogle Scholar
  10. 10.
    Scheller MS, Sears KL. Postoperative neurologic dysfunction associated with preoperative administration of metoclopramide. Anesth Analg 1987; 66: 274–6.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 1994

Authors and Affiliations

  • Yoshitaka Fujii
    • 1
  • Hiroyoshi Tanaka
    • 1
  • Hidenori Toyooka
    • 2
  1. 1.Department of AnaesthesiologyToride Kyodo General HospitalToride City, IbarakiJapan
  2. 2.Department of Anaesthesiology and Critical Care MedicineTokyo Medical and Dental University School of MedicineTokyoJapan

Personalised recommendations